China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval from the Indonesian Food and Drug Control Agency (BPOM) for its Weuphoria, a 13-valent pneumococcal polysaccharide conjugate vaccine (PCV-13). This approval is a significant milestone for Walvax as it expands its reach into the Indonesian market, where the vaccine is set to play a crucial role in public health.
Indonesia’s Vaccination Program
Indonesia has been proactive in its vaccination efforts, having carried out a three-year PCV-13 vaccination pilot program from 2017 to 2019, achieving a vaccination coverage rate of over 80% each year. Walvax’s Weuphoria was integrated into Indonesia’s national vaccination program in 2020 and has been promoted nationwide since March 2022.
Impact and Administration
The Weuphoria vaccine is expected to be administered to 12 million newborns in Indonesia each year, significantly contributing to the country’s immunization goals. Walvax Bio’s 13-valent pneumococcal polysaccharide conjugate vaccine is designed to effectively prevent diseases caused by 13 serotypes of pneumococci in infants and young children aged 6 weeks to 5 years, thereby improving immunity and providing efficient protection for Indonesian children.-Fineline Info & Tech
